Identification

Name
Desvenlafaxine
Accession Number
DB06700
Type
Small Molecule
Groups
Approved, Investigational
Description

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Structure
Thumb
Synonyms
  • Desvenlafaxine
  • O-desmethylvenlafaxine
  • ODV
Product Ingredients
IngredientUNIICASInChI Key
Desvenlafaxine fumarateATX24E9M6L93414-04-1SQTJDJZCPOSWSC-WLHGVMLRSA-N
Desvenlafaxine fumarate monohydrateR5JHD7L72A313471-75-9YETWCSLOYUZBLK-JITBQSAISA-N
Desvenlafaxine succinateZB22ENF0XR386750-22-7ORUUBRMVQCKYHB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesvenlafaxineTablet, extended release100 mg/1OralSun Pharma Global FZE2014-01-302017-02-08Us
DesvenlafaxineTablet, extended release100 mg/1OralSun Pharmaceutical Industries Limited2013-03-05Not applicableUs63304 0192 30 nlmimage10 9544ca96
DesvenlafaxineTablet, extended release50 mg/1OralSun Pharma Global FZE2014-01-302017-02-08Us
DesvenlafaxineTablet, extended release50 mg/1OralSun Pharmaceutical Industries Limited2013-03-05Not applicableUs63304 0191 30 nlmimage10 aa405562
Khedezla Extended-releaseTablet, extended release50 mg/1OralPar Pharmaceutical2013-07-102016-10-29Us
Khedezla Extended-releaseTablet, extended release50 mg/1OralPernix Therapeutics2013-07-10Not applicableUs
Khedezla Extended-releaseTablet, extended release100 mg/1OralPar Pharmaceutical2013-07-102016-10-29Us
Khedezla Extended-releaseTablet, extended release100 mg/1OralPernix Therapeutics2013-07-10Not applicableUs
PristiqTablet, extended release100 mgOralPfizer2009-03-06Not applicableCanada
PristiqTablet, extended release50 mgOralPfizer2009-03-05Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-desvenlafaxineTablet, extended release50 mgOralApotex Corporation2017-10-20Not applicableCanada
Apo-desvenlafaxineTablet, extended release100 mgOralApotex Corporation2017-10-20Not applicableCanada
DesvenlafaxineTablet, film coated, extended release50 mg/1Oralbryant ranch prepack2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralActavis Pharma Company2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralGolden State Medical Supply2018-01-01Not applicableUs
DesvenlafaxineTablet, film coated, extended release50 mg/1OralMylan Pharmaceuticals2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1OralBreckenridge Pharmaceutical, Inc.2015-07-13Not applicableUs
DesvenlafaxineTablet, extended release50 mg/1OralCadila Pharnmaceuticals2018-05-08Not applicableUs
DesvenlafaxineTablet, film coated, extended release50 mg/1OralCarilion Materials Management2017-03-01Not applicableUs
DesvenlafaxineTablet, extended release100 mg/1Oralbryant ranch prepack2017-03-01Not applicableUs
International/Other Brands
Pristiq / Zyven-OD
Categories
UNII
NG99554ANW
CAS number
93413-62-8
Weight
Average: 263.3752
Monoisotopic: 263.188529049
Chemical Formula
C16H25NO2
InChI Key
KYYIDSXMWOZKMP-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
IUPAC Name
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
SMILES
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1

Pharmacology

Indication

Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.

Associated Conditions
Pharmacodynamics

Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic dose. Some of the limitations of desvenlafaxine include moderate efficacy in the treatment of major depressive disorder, similar safety and tolerability profile to other SNRIs and possible transient discontinuation symptoms upon cessation of therapy.

Mechanism of action

Desvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
Absorption

Absolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.

Volume of distribution

3.4 L/kg, distribution into nonvascular compartments

Protein binding

~ 30%, protein binding is independent of drug concentration.

Metabolism

The primary route of metabolism is via conjugation mediated by UGT isoforms. Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent. CYP2D6 is not involved with the metabolism of desvenlafaxine.

Route of elimination

Excreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.

Half life

The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.

Clearance
Not Available
Toxicity

The safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Venlafaxine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineDesvenlafaxine may increase the tachycardic activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Desvenlafaxine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desvenlafaxine.Experimental
AcarboseDesvenlafaxine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
AceclofenacDesvenlafaxine may increase the antiplatelet activities of Aceclofenac.Approved, Investigational
AcenocoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Desvenlafaxine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desvenlafaxine.Approved
AcetaminophenDesvenlafaxine may increase the antiplatelet activities of Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Desvenlafaxine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidDesvenlafaxine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Desvenlafaxine.Investigational
AdrafinilDesvenlafaxine may increase the tachycardic activities of Adrafinil.Withdrawn
AgmatineDesvenlafaxine may increase the tachycardic activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desvenlafaxine.Approved, Investigational
AlaproclateDesvenlafaxine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideDesvenlafaxine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desvenlafaxine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Desvenlafaxine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desvenlafaxine.Approved, Investigational
AlogliptinDesvenlafaxine may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Desvenlafaxine.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Desvenlafaxine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desvenlafaxine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Desvenlafaxine.Approved, Withdrawn
AmibegronDesvenlafaxine may increase the tachycardic activities of Amibegron.Investigational
Aminosalicylic AcidDesvenlafaxine may increase the antiplatelet activities of Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Desvenlafaxine.Approved, Investigational
AmitrazDesvenlafaxine may increase the tachycardic activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desvenlafaxine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desvenlafaxine.Approved, Illicit
AmoxapineDesvenlafaxine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Desvenlafaxine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amphetamine.Approved, Illicit, Investigational
AnisodamineDesvenlafaxine may increase the tachycardic activities of Anisodamine.Investigational
AntipyrineDesvenlafaxine may increase the antiplatelet activities of Antipyrine.Approved, Investigational
AntrafenineDesvenlafaxine may increase the antiplatelet activities of Antrafenine.Approved
ApalutamideThe serum concentration of Desvenlafaxine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineDesvenlafaxine may increase the tachycardic activities of Apomorphine.Approved, Investigational
ApraclonidineDesvenlafaxine may increase the tachycardic activities of Apraclonidine.Approved
AprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineDesvenlafaxine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolDesvenlafaxine may increase the tachycardic activities of Arformoterol.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Desvenlafaxine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Desvenlafaxine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desvenlafaxine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Desvenlafaxine.Approved
AtomoxetineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Desvenlafaxine.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desvenlafaxine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desvenlafaxine.Approved
BalsalazideDesvenlafaxine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
BambuterolDesvenlafaxine may increase the tachycardic activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.Illicit
BefunololDesvenlafaxine may increase the tachycardic activities of Befunolol.Experimental
BendroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Desvenlafaxine.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desvenlafaxine.Approved, Investigational
BenzphetamineDesvenlafaxine may increase the tachycardic activities of Benzphetamine.Approved, Illicit
BenzthiazideDesvenlafaxine may increase the hyponatremic activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desvenlafaxine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
BethanidineDesvenlafaxine may decrease the antihypertensive activities of Bethanidine.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Desvenlafaxine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved
BezitramideBezitramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Bifeprunox.Investigational
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Desvenlafaxine.Approved
BitolterolDesvenlafaxine may increase the tachycardic activities of Bitolterol.Withdrawn
BoceprevirThe metabolism of Desvenlafaxine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Desvenlafaxine.Approved
BortezomibThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brexpiprazole.Approved, Investigational
BrimonidineDesvenlafaxine may increase the tachycardic activities of Brimonidine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desvenlafaxine.Approved, Illicit, Investigational
BromfenacDesvenlafaxine may increase the antiplatelet activities of Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Desvenlafaxine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Desvenlafaxine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desvenlafaxine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine.Investigational
BufexamacDesvenlafaxine may increase the antiplatelet activities of Bufexamac.Approved, Experimental
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Desvenlafaxine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desvenlafaxine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Desvenlafaxine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desvenlafaxine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Desvenlafaxine.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Desvenlafaxine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desvenlafaxine.Approved
CanagliflozinDesvenlafaxine may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Desvenlafaxine.Investigational
CapsaicinDesvenlafaxine may increase the antiplatelet activities of Capsaicin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Desvenlafaxine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desvenlafaxine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Desvenlafaxine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desvenlafaxine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Caroxazone.Withdrawn
CarprofenDesvenlafaxine may increase the antiplatelet activities of Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Desvenlafaxine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CelecoxibDesvenlafaxine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololDesvenlafaxine may increase the tachycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desvenlafaxine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desvenlafaxine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desvenlafaxine.Approved
ChlorothiazideDesvenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine.Approved
ChlorphenesinDesvenlafaxine may increase the antiplatelet activities of Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
ChlorpropamideDesvenlafaxine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ChlorthalidoneDesvenlafaxine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desvenlafaxine.Approved
Choline magnesium trisalicylateDesvenlafaxine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
CimetidineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibDesvenlafaxine may increase the antiplatelet activities of Cimicoxib.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desvenlafaxine.Approved, Vet Approved
CirazolineDesvenlafaxine may increase the tachycardic activities of Cirazoline.Experimental
CisplatinDesvenlafaxine may increase the antiplatelet activities of Cisplatin.Approved
CitalopramDesvenlafaxine may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Desvenlafaxine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolDesvenlafaxine may increase the tachycardic activities of Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desvenlafaxine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Desvenlafaxine.Approved, Illicit
Clodronic AcidDesvenlafaxine may increase the antiplatelet activities of Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Desvenlafaxine.Investigational
ClomipramineDesvenlafaxine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Desvenlafaxine.Approved, Illicit
ClonidineDesvenlafaxine may increase the tachycardic activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Desvenlafaxine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Desvenlafaxine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desvenlafaxine.Approved, Illicit
ClorindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Desvenlafaxine.Experimental
ClotrimazoleThe metabolism of Desvenlafaxine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Desvenlafaxine.Approved
CobicistatThe metabolism of Desvenlafaxine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desvenlafaxine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Desvenlafaxine.Approved, Investigational
CrizotinibThe metabolism of Desvenlafaxine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Desvenlafaxine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Desvenlafaxine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved
CyclopenthiazideDesvenlafaxine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Desvenlafaxine.Experimental
CyclosporineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Desvenlafaxine.Approved, Investigational
DapagliflozinDesvenlafaxine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desvenlafaxine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.Investigational
DarunavirThe metabolism of Desvenlafaxine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Desvenlafaxine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Desvenlafaxine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desvenlafaxine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desvenlafaxine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.Approved
DetomidineDesvenlafaxine may increase the tachycardic activities of Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine.Approved
DexibuprofenDesvenlafaxine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexketoprofenDesvenlafaxine may increase the antiplatelet activities of Dexketoprofen.Approved, Investigational
DexmedetomidineDesvenlafaxine may increase the tachycardic activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanDesvenlafaxine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
DiclofenacDesvenlafaxine may increase the antiplatelet activities of Diclofenac.Approved, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Desvenlafaxine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Desvenlafaxine.Approved, Illicit
DiflunisalDesvenlafaxine may increase the antiplatelet activities of Diflunisal.Approved, Investigational
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desvenlafaxine.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Desvenlafaxine.Experimental, Illicit
DiltiazemThe metabolism of Desvenlafaxine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desvenlafaxine.Approved
DiphenadioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desvenlafaxine.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
DipivefrinDesvenlafaxine may increase the tachycardic activities of Dipivefrin.Approved
DisopyramideDesvenlafaxine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Desvenlafaxine.Experimental
DL-MethylephedrineDesvenlafaxine may increase the tachycardic activities of DL-Methylephedrine.Approved
DobutamineDesvenlafaxine may increase the tachycardic activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DopexamineDesvenlafaxine may increase the tachycardic activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Desvenlafaxine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Desvenlafaxine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.Approved, Investigational
DoxofyllineDesvenlafaxine may increase the tachycardic activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Desvenlafaxine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Desvenlafaxine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Desvenlafaxine.Experimental
DronedaroneThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Desvenlafaxine.Approved, Vet Approved
DrospirenoneDesvenlafaxine may increase the antiplatelet activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Desvenlafaxine.Experimental, Illicit
DroxicamDesvenlafaxine may increase the antiplatelet activities of Droxicam.Withdrawn
DroxidopaDesvenlafaxine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DulaglutideDesvenlafaxine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Desvenlafaxine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desvenlafaxine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desvenlafaxine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desvenlafaxine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Desvenlafaxine.Investigational
EmpagliflozinDesvenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desvenlafaxine.Approved, Investigational
EnzalutamideThe serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Desvenlafaxine.Experimental
EphedraDesvenlafaxine may increase the tachycardic activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDesvenlafaxine may increase the tachycardic activities of Ephedrine.Approved
EpinastineDesvenlafaxine may increase the tachycardic activities of Epinastine.Approved, Investigational
EpinephrineDesvenlafaxine may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
EpitizideDesvenlafaxine may increase the hyponatremic activities of Epitizide.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desvenlafaxine.Approved
ErythromycinThe metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe serum concentration of Esatenolol can be increased when it is combined with Desvenlafaxine.Experimental
EscitalopramDesvenlafaxine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desvenlafaxine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desvenlafaxine.Approved, Investigational
EtafedrineDesvenlafaxine may increase the tachycardic activities of Etafedrine.Approved
EtanerceptDesvenlafaxine may increase the antiplatelet activities of Etanercept.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desvenlafaxine.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Desvenlafaxine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desvenlafaxine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Desvenlafaxine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Desvenlafaxine.Investigational, Withdrawn
EtilefrineDesvenlafaxine may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Desvenlafaxine.Approved
EtodolacDesvenlafaxine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateDesvenlafaxine may increase the tachycardic activities of Etomidate.Approved
EtoricoxibDesvenlafaxine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Desvenlafaxine.Illicit, Vet Approved
ExenatideDesvenlafaxine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Desvenlafaxine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desvenlafaxine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
FenfluramineDesvenlafaxine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenDesvenlafaxine may increase the antiplatelet activities of Fenoprofen.Approved
FenoterolDesvenlafaxine may increase the tachycardic activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desvenlafaxine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desvenlafaxine.Approved, Investigational
Fish oilDesvenlafaxine may increase the antiplatelet activities of Fish oil.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Desvenlafaxine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Desvenlafaxine.Experimental
FluconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.Approved, Illicit
FluindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Desvenlafaxine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desvenlafaxine.Approved, Illicit
FluoxetineDesvenlafaxine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desvenlafaxine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desvenlafaxine.Approved, Illicit, Investigational
FlurbiprofenDesvenlafaxine may increase the antiplatelet activities of Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desvenlafaxine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desvenlafaxine.Approved
FluvoxamineDesvenlafaxine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolDesvenlafaxine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Desvenlafaxine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Desvenlafaxine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desvenlafaxine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Desvenlafaxine.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Desvenlafaxine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Desvenlafaxine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Desvenlafaxine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desvenlafaxine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Desvenlafaxine.Investigational
GinsengDesvenlafaxine may increase the antiplatelet activities of Ginseng.Approved, Investigational, Nutraceutical
GliclazideDesvenlafaxine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDesvenlafaxine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDesvenlafaxine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Desvenlafaxine.Approved, Illicit
GlyburideDesvenlafaxine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
GuanabenzDesvenlafaxine may increase the tachycardic activities of Guanabenz.Approved, Investigational
GuanfacineDesvenlafaxine may increase the tachycardic activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desvenlafaxine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desvenlafaxine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desvenlafaxine.Approved
HexoprenalineDesvenlafaxine may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HigenamineDesvenlafaxine may increase the tachycardic activities of Higenamine.Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Hydracarbazine.Experimental
HydrochlorothiazideDesvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
HydroflumethiazideDesvenlafaxine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Desvenlafaxine.Approved
IbuprofenDesvenlafaxine may increase the antiplatelet activities of Ibuprofen.Approved
IcosapentDesvenlafaxine may increase the antiplatelet activities of Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Desvenlafaxine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.Approved
ImatinibThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.Approved
IndacaterolDesvenlafaxine may increase the tachycardic activities of Indacaterol.Approved
IndalpineDesvenlafaxine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideDesvenlafaxine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Desvenlafaxine.Withdrawn
IndinavirThe metabolism of Desvenlafaxine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Desvenlafaxine.Investigational
IndomethacinDesvenlafaxine may increase the antiplatelet activities of Indomethacin.Approved, Investigational
Insulin AspartDesvenlafaxine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDesvenlafaxine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDesvenlafaxine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDesvenlafaxine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDesvenlafaxine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDesvenlafaxine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desvenlafaxine.Approved, Investigational
Ioflupane I-123Desvenlafaxine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Desvenlafaxine.Withdrawn
IsavuconazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Desvenlafaxine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Desvenlafaxine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineDesvenlafaxine may increase the tachycardic activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desvenlafaxine.Approved, Vet Approved
IsomethepteneDesvenlafaxine may increase the tachycardic activities of Isometheptene.Approved
IsoprenalineDesvenlafaxine may increase the tachycardic activities of Isoprenaline.Approved, Investigational
IsoxsuprineDesvenlafaxine may increase the tachycardic activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Desvenlafaxine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desvenlafaxine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desvenlafaxine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
KetoconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenDesvenlafaxine may increase the antiplatelet activities of Ketoprofen.Approved, Vet Approved
KetorolacDesvenlafaxine may increase the antiplatelet activities of Ketorolac.Approved
L-TryptophanL-Tryptophan may increase the serotonergic activities of Desvenlafaxine.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lamotrigine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Desvenlafaxine.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desvenlafaxine.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Desvenlafaxine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desvenlafaxine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Desvenlafaxine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Desvenlafaxine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Desvenlafaxine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
LevomilnacipranDesvenlafaxine may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LevonordefrinDesvenlafaxine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Desvenlafaxine.Approved
LevosalbutamolDesvenlafaxine may increase the tachycardic activities of Levosalbutamol.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Desvenlafaxine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Desvenlafaxine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Desvenlafaxine.Approved
LiraglutideDesvenlafaxine may increase the hypoglycemic activities of Liraglutide.Approved
Lithium cationLithium may increase the serotonergic activities of Desvenlafaxine.Experimental
LofentanilLofentanil may increase the serotonergic activities of Desvenlafaxine.Illicit
LofexidineDesvenlafaxine may increase the tachycardic activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Desvenlafaxine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desvenlafaxine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desvenlafaxine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Desvenlafaxine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Desvenlafaxine.Approved
LornoxicamDesvenlafaxine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Desvenlafaxine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desvenlafaxine.Approved
LuliconazoleThe serum concentration of Desvenlafaxine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Desvenlafaxine can be increased when combined with Lumacaftor.Approved
LumiracoxibDesvenlafaxine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desvenlafaxine.Approved, Investigational
Magnesium salicylateDesvenlafaxine may increase the antiplatelet activities of Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Desvenlafaxine.Experimental
MecaserminDesvenlafaxine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desvenlafaxine.Approved
Meclofenamic acidDesvenlafaxine may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Desvenlafaxine.Experimental
MedetomidineDesvenlafaxine may increase the tachycardic activities of Medetomidine.Vet Approved
Mefenamic acidDesvenlafaxine may increase the antiplatelet activities of Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desvenlafaxine.Approved, Nutraceutical, Vet Approved
MeloxicamDesvenlafaxine may increase the antiplatelet activities of Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Desvenlafaxine.Approved, Investigational
MephentermineDesvenlafaxine may increase the tachycardic activities of Mephentermine.Approved
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Desvenlafaxine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desvenlafaxine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Desvenlafaxine.Experimental
MesalazineDesvenlafaxine may increase the antiplatelet activities of Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desvenlafaxine.Approved, Investigational
MetaraminolDesvenlafaxine may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desvenlafaxine.Approved
MetforminDesvenlafaxine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Desvenlafaxine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
MethamphetamineDesvenlafaxine may increase the tachycardic activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desvenlafaxine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desvenlafaxine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desvenlafaxine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desvenlafaxine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Desvenlafaxine.Approved, Investigational
MethoxamineDesvenlafaxine may increase the tachycardic activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
MethoxyphenamineDesvenlafaxine may increase the tachycardic activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.Approved
MethyclothiazideDesvenlafaxine may increase the hyponatremic activities of Methyclothiazide.Approved
MethyldopaDesvenlafaxine may increase the tachycardic activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desvenlafaxine.Experimental
Methylene blueDesvenlafaxine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desvenlafaxine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Desvenlafaxine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.Approved, Investigational
MetolazoneDesvenlafaxine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Desvenlafaxine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desvenlafaxine.Approved, Illicit
MidodrineDesvenlafaxine may increase the tachycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Desvenlafaxine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolDesvenlafaxine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranDesvenlafaxine may increase the serotonergic activities of Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Desvenlafaxine.Approved
MirabegronDesvenlafaxine may increase the tachycardic activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desvenlafaxine.Approved
MitotaneThe serum concentration of Desvenlafaxine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Desvenlafaxine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Moperone.Experimental
MorniflumateDesvenlafaxine may increase the antiplatelet activities of Morniflumate.Approved
MorphineMorphine may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mosapramine.Experimental
MoxonidineDesvenlafaxine may increase the tachycardic activities of Moxonidine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Desvenlafaxine.Approved, Investigational
NabumetoneDesvenlafaxine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Desvenlafaxine.Approved
NaphazolineDesvenlafaxine may increase the tachycardic activities of Naphazoline.Approved
NaproxenDesvenlafaxine may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Desvenlafaxine.Approved, Investigational
NateglinideDesvenlafaxine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololDesvenlafaxine may increase the tachycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.Approved
NepafenacDesvenlafaxine may increase the antiplatelet activities of Nepafenac.Approved, Investigational
NetupitantThe serum concentration of Desvenlafaxine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Desvenlafaxine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Desvenlafaxine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Desvenlafaxine.Experimental
Niflumic AcidDesvenlafaxine may increase the antiplatelet activities of Niflumic Acid.Approved
NilotinibThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideDesvenlafaxine may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desvenlafaxine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desvenlafaxine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Desvenlafaxine.Approved
NorepinephrineDesvenlafaxine may increase the tachycardic activities of Norepinephrine.Approved
NorfenefrineDesvenlafaxine may increase the tachycardic activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Desvenlafaxine.Approved, Investigational
NormethadoneNormethadone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desvenlafaxine.Approved
NylidrinDesvenlafaxine may increase the tachycardic activities of Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Octamoxin.Withdrawn
OctopamineDesvenlafaxine may increase the tachycardic activities of Octopamine.Experimental
OlanzapineDesvenlafaxine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.Approved
OlodaterolDesvenlafaxine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desvenlafaxine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desvenlafaxine.Approved
OpiumOpium may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit
OrciprenalineDesvenlafaxine may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desvenlafaxine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Desvenlafaxine.Investigational
OsimertinibThe serum concentration of Desvenlafaxine can be increased when it is combined with Osimertinib.Approved
OxaprozinDesvenlafaxine may increase the antiplatelet activities of Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Desvenlafaxine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desvenlafaxine.Approved, Investigational
OxycodoneOxycodone may increase the serotonergic activities of Desvenlafaxine.Approved, Illicit, Investigational
OxyfedrineDesvenlafaxine may increase the tachycardic activities of Oxyfedrine.Experimental
OxymetazolineDesvenlafaxine may increase the tachycardic activities of Oxymetazoline.Approved, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneDesvenlafaxine may increase the tachycardic activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desvenlafaxine.Approved, Investigational
ParecoxibDesvenlafaxine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Desvenlafaxine.Approved
ParoxetineDesvenlafaxine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Desvenlafaxine.Experimental
PentamidineDesvenlafaxine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocinePentazocine may increase the serotonergic activities of Desvenlafaxine.Approved, Vet Approved
PentobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Desvenlafaxine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Desvenlafaxine.Approved, Investigational
PergolideDesvenlafaxine may increase the tachycardic activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Desvenlafaxine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desvenlafaxine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desvenlafaxine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Desvenlafaxine.Experimental
PhendimetrazineDesvenlafaxine may increase the tachycardic activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Desvenlafaxine.Experimental
PhenindioneThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Desvenlafaxine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidinePhenoperidine may increase the serotonergic activities of Desvenlafaxine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desvenlafaxine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenoxypropazine.Withdrawn
PhenprocoumonThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Phenprocoumon.Approved, Investigational
PhenylbutazoneDesvenlafaxine may increase the antiplatelet activities of Phenylbutazone.Approved, Vet Approved
PhenylephrineDesvenlafaxine may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineDesvenlafaxine may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Desvenlafaxine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desvenlafaxine.Approved
PindololDesvenlafaxine may increase the tachycardic activities of Pindolol.Approved, Investigational
PioglitazoneDesvenlafaxine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desvenlafaxine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipotiazine.Approved, Investigational
PirbuterolDesvenlafaxine may increase the tachycardic activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Desvenlafaxine.Approved
PiroxicamDesvenlafaxine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
PitolisantThe serum concentration of Desvenlafaxine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Desvenlafaxine.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Desvenlafaxine.Experimental
PolythiazideDesvenlafaxine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desvenlafaxine.Approved
PosaconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Desvenlafaxine.Approved
PramlintideDesvenlafaxine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desvenlafaxine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desvenlafaxine.Approved, Illicit, Investigational
PrenalterolDesvenlafaxine may increase the tachycardic activities of Prenalterol.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desvenlafaxine.Approved
PrimidoneThe metabolism of Desvenlafaxine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Procarbazine.Approved, Investigational
ProcaterolDesvenlafaxine may increase the tachycardic activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desvenlafaxine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desvenlafaxine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desvenlafaxine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Desvenlafaxine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Desvenlafaxine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desvenlafaxine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Desvenlafaxine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prothipendyl.Investigational
ProtokylolDesvenlafaxine may increase the tachycardic activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Desvenlafaxine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Desvenlafaxine.Investigational
PseudoephedrineDesvenlafaxine may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desvenlafaxine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desvenlafaxine.Approved
QuinethazoneDesvenlafaxine may increase the hyponatremic activities of Quinethazone.Approved
QuinineDesvenlafaxine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Desvenlafaxine.Experimental
RacepinephrineDesvenlafaxine may increase the tachycardic activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Desvenlafaxine.Investigational
RactopamineDesvenlafaxine may increase the tachycardic activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine.Approved, Investigational
RanolazineThe metabolism of Desvenlafaxine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Desvenlafaxine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desvenlafaxine.Approved, Withdrawn
RepaglinideDesvenlafaxine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReproterolDesvenlafaxine may increase the tachycardic activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desvenlafaxine.Approved, Investigational
ResveratrolDesvenlafaxine may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
RifabutinThe metabolism of Desvenlafaxine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Desvenlafaxine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Desvenlafaxine can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineDesvenlafaxine may increase the tachycardic activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Desvenlafaxine.Approved
RimiterolDesvenlafaxine may increase the tachycardic activities of Rimiterol.Experimental
RisperidoneThe metabolism of Risperidone can be decreased when combined with Desvenlafaxine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Desvenlafaxine.Investigational
RitobegronDesvenlafaxine may increase the tachycardic activities of Ritobegron.Investigational
RitodrineDesvenlafaxine may increase the tachycardic activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Desvenlafaxine.Approved
RofecoxibDesvenlafaxine may increase the antiplatelet activities of Rofecoxib.Approved, Investigational, Withdrawn
RomifidineDesvenlafaxine may increase the tachycardic activities of Romifidine.Vet Approved
RopiniroleDesvenlafaxine may increase the tachycardic activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine.Approved
RosiglitazoneDesvenlafaxine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RucaparibThe metabolism of Desvenlafaxine can be decreased when combined with Rucaparib.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Safrazine.Withdrawn
SalbutamolDesvenlafaxine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
Salicylic acidDesvenlafaxine may increase the antiplatelet activities of Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolDesvenlafaxine may increase the tachycardic activities of Salmeterol.Approved
SalsalateDesvenlafaxine may increase the antiplatelet activities of Salsalate.Approved
SaquinavirThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Desvenlafaxine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Selegiline.Approved, Investigational, Vet Approved
SeliciclibDesvenlafaxine may increase the antiplatelet activities of Seliciclib.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Desvenlafaxine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
SertralineDesvenlafaxine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desvenlafaxine.Approved, Vet Approved
SildenafilThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Desvenlafaxine can be increased when it is combined with Simeprevir.Approved
SitagliptinDesvenlafaxine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Desvenlafaxine.Approved
SolabegronDesvenlafaxine may increase the tachycardic activities of Solabegron.Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Desvenlafaxine.Approved
St. John's WortThe serum concentration of Desvenlafaxine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Desvenlafaxine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
SulfadiazineDesvenlafaxine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleDesvenlafaxine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineDesvenlafaxine may increase the antiplatelet activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Desvenlafaxine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacDesvenlafaxine may increase the antiplatelet activities of Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desvenlafaxine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Desvenlafaxine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Desvenlafaxine.Approved, Investigational
SunitinibDesvenlafaxine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenDesvenlafaxine may increase the antiplatelet activities of Suprofen.Approved, Withdrawn
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Desvenlafaxine.Approved, Investigational
SynephrineDesvenlafaxine may increase the tachycardic activities of Synephrine.Experimental
TalinololThe serum concentration of Talinolol can be increased when it is combined with Desvenlafaxine.Investigational
TalniflumateDesvenlafaxine may increase the antiplatelet activities of Talniflumate.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Desvenlafaxine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desvenlafaxine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Desvenlafaxine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Desvenlafaxine.Approved
TelaprevirThe metabolism of Desvenlafaxine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Desvenlafaxine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desvenlafaxine.Approved, Investigational
TenoxicamDesvenlafaxine may increase the antiplatelet activities of Tenoxicam.Approved
TerbutalineDesvenlafaxine may increase the tachycardic activities of Terbutaline.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Desvenlafaxine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Desvenlafaxine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desvenlafaxine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desvenlafaxine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desvenlafaxine.Investigational
TetryzolineDesvenlafaxine may increase the tachycardic activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desvenlafaxine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desvenlafaxine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desvenlafaxine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desvenlafaxine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Desvenlafaxine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desvenlafaxine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Desvenlafaxine.Approved, Investigational
Tiaprofenic acidDesvenlafaxine may increase the antiplatelet activities of Tiaprofenic acid.Approved
TiclopidineThe metabolism of Desvenlafaxine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Desvenlafaxine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Desvenlafaxine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Desvenlafaxine.Approved
TioclomarolThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tioclomarol.Experimental
TizanidineDesvenlafaxine may increase the tachycardic activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.Approved
TolazamideDesvenlafaxine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideDesvenlafaxine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desvenlafaxine.Approved, Withdrawn
TolmetinDesvenlafaxine may increase the antiplatelet activities of Tolmetin.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Desvenlafaxine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Desvenlafaxine.Approved
TramadolDesvenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tranylcypromine.Approved, Investigational
TrazodoneDesvenlafaxine may increase the serotonergic activities of Trazodone.Approved, Investigational
TretoquinolDesvenlafaxine may increase the tachycardic activities of Tretoquinol.Experimental
TriamcinoloneDesvenlafaxine may increase the antiplatelet activities of Triamcinolone.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desvenlafaxine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Desvenlafaxine.Vet Approved
TrichlormethiazideDesvenlafaxine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Desvenlafaxine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desvenlafaxine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Desvenlafaxine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desvenlafaxine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desvenlafaxine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desvenlafaxine.Approved
Trolamine salicylateDesvenlafaxine may increase the antiplatelet activities of Trolamine salicylate.Approved
TropisetronTropisetron may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
TulobuterolDesvenlafaxine may increase the tachycardic activities of Tulobuterol.Investigational
ValdecoxibDesvenlafaxine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desvenlafaxine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Desvenlafaxine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Desvenlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Desvenlafaxine.Experimental
VerapamilThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Desvenlafaxine.Approved
VilanterolDesvenlafaxine may increase the tachycardic activities of Vilanterol.Approved
VilazodoneDesvenlafaxine may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Desvenlafaxine.Experimental
VoriconazoleThe metabolism of Desvenlafaxine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineDesvenlafaxine may increase the serotonergic activities of Vortioxetine.Approved, Investigational
WarfarinThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Warfarin.Approved
XamoterolDesvenlafaxine may increase the tachycardic activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Desvenlafaxine.Experimental
XylazineDesvenlafaxine may increase the tachycardic activities of Xylazine.Vet Approved
XylometazolineDesvenlafaxine may increase the tachycardic activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Desvenlafaxine.Approved
ZimelidineDesvenlafaxine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Desvenlafaxine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desvenlafaxine.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desvenlafaxine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desvenlafaxine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desvenlafaxine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Desvenlafaxine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desvenlafaxine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Karel Pospisilik, Lambertus Thijs, "Process for making desvenlafaxine." U.S. Patent US20070299283, issued December 27, 2007.

US20070299283
General References
  1. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [PubMed:20926994]
  2. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  3. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [PubMed:20797382]
  4. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  5. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  6. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. doi: 10.1097/YIC.0b013e32832fbb5a. [PubMed:19779354]
  7. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. [PubMed:19629022]
  8. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. [PubMed:19127490]
  9. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]
  10. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230]
  11. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. [PubMed:19142106]
  12. Link [Link]
External Links
Human Metabolome Database
HMDB0015646
KEGG Drug
D02570
PubChem Compound
125017
PubChem Substance
99443254
ChemSpider
111300
BindingDB
86748
ChEBI
83527
ChEMBL
CHEMBL1118
PharmGKB
PA165958374
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Desvenlafaxine
ATC Codes
N06AX23 — Desvenlafaxine
AHFS Codes
  • 28:16.04.16 — Selective Serotonin and Norepinephrine-reuptake Inhibitors
FDA label
Download (379 KB)
MSDS
Download (86.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceMajor Depressive Disorder (MDD)1
1CompletedOtherHealthy Volunteers3
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMajor Depressive Disorder (MDD)3
1Unknown StatusBasic ScienceHealthy Volunteers1
1WithdrawnOtherHepatic Impairment1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3TerminatedTreatmentCancers / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression1
3CompletedTreatmentMajor Depressive Disorder (MDD)5
3Unknown StatusTreatmentMajor Depressive Disorder (MDD) / Menopausal Staging and Vasomotor Symptoms (for Females)1
4CompletedBasic ScienceCYP3A4 Protein, Human / Cytochrome P-450 CYP2D6 / Pharmacokinetics1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedTreatmentChronic Depressive Disorder / Dysthymic Disorder1
4CompletedTreatmentDepression / Methadone Treatment / Opioid Dependence1
4CompletedTreatmentMajor Depressive Disorder (MDD)2
4CompletedTreatmentSocial Anxiety Disorder (SAD)1
4RecruitingOtherAnhedonia / Depression1
4RecruitingTreatmentGeneralized Anxiety Disorder (GAD)1
4RecruitingTreatmentMenopausal Hot Flushes / Neoplasms, Breast1
4RecruitingTreatmentVascular Depression1
4TerminatedNot AvailableMajor Depressive Disorder (MDD) / Vasomotor Symptoms1
4Unknown StatusBasic ScienceMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedTreatmentDysthymic Disorder1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral50 mg
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Pristiq 100 mg extended-release tablet4.46USD tablet
Pristiq 50 mg extended-release tablet4.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2436668No2009-05-262022-02-11Canada
US6673838No2002-03-012022-03-01Us
US8269040No2007-07-052027-07-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble FDA label
logP0.21FDA label
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP2.6ALOGPS
logP2.29ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.54 m3·mol-1ChemAxon
Polarizability30.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.7722
Caco-2 permeable+0.8404
P-glycoprotein substrateSubstrate0.6918
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IIInhibitor0.5921
Renal organic cation transporterNon-inhibitor0.5894
CYP450 2C9 substrateNon-substrate0.7837
CYP450 2D6 substrateSubstrate0.7753
CYP450 3A4 substrateSubstrate0.6997
CYP450 1A2 substrateNon-inhibitor0.6816
CYP450 2C9 inhibitorNon-inhibitor0.757
CYP450 2D6 inhibitorInhibitor0.6334
CYP450 2C19 inhibitorNon-inhibitor0.7811
CYP450 3A4 inhibitorNon-inhibitor0.8646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8888
Ames testNon AMES toxic0.8084
CarcinogenicityNon-carcinogens0.7648
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4429 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6046
hERG inhibition (predictor II)Inhibitor0.5603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03di-0090000000-90abc876cc91a398d25d
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03y0-0960000000-0219d7d7ea1a46c8cfdf
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-529d7fb237a99866f0b4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-ccb6c8906a1ac7d27cd6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0290000000-422a5daa0d4bf51308ef
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0910000000-03ecfc411d730c35b892
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-d0fa1892dfaae0510ee8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001m-0900000000-7515704132219cf15c78
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-1a8bdddd358a8706e896
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-c218ef4ab652831ee930
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06r2-4090000000-b1767a9c9c01cb43bca9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9320000000-e38b2ae07ab3cc9b7693
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9600000000-edbb26312a47b22bffb7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-b41801091e3c7132fec9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-4b30d7e9d71dab81d9d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090000000-5e859f484b6e3a5560c4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06r2-4090000000-ef1215dc6fc4eb904b90
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9310000000-dac7bd983af34469bc5f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9600000000-8ea073e198c8a9a9a528
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-f8db755a9bb1f788394e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9700000000-b50718dbaca8fdae5401
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-7ed75e3f487ccd4f981d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0bta-6090000000-c41286a6446e8e51aab6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9100000000-e80f225fbf61adb457b7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-9200000000-81250c46509f91e0409b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9400000000-b6e08db8ef3bea2640a3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9500000000-6ece9a9beebd1cd99bfd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9400000000-5411c26ee28734211eb5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-2090000000-134bece44509731dae98
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9150000000-383ebf283bfe27d5b20f

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclohexanols. These are compounds containing an alcohol group attached to a cyclohexane ring.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Alcohols and polyols
Direct Parent
Cyclohexanols
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / Cyclohexanol / Phenol / Aralkylamine / Monocyclic benzene moiety / Benzenoid / 1,3-aminoalcohol / Cyclic alcohol / Tertiary alcohol / Tertiary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, phenols, cyclohexanols (CHEBI:83527)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [PubMed:16675639]
  2. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [PubMed:17673606]
  3. Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [PubMed:19698900]
  4. Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [PubMed:19086875]
  5. Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [PubMed:20944767]
  6. Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [PubMed:19919295]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [PubMed:22098230]

Drug created on May 06, 2010 10:22 / Updated on July 16, 2018 21:31